Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.